Reviva Financial Statements From 2010 to 2025

RVPHW Stock  USD 0.14  0.01  7.69%   
Reviva Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Reviva Pharmaceuticals Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Reviva Pharmaceuticals financial statements helps investors assess Reviva Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Reviva Pharmaceuticals' valuation are summarized below:
Reviva Pharmaceuticals Holdings does not presently have any trending fundamental ratios for analysis.
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.

Reviva Pharmaceuticals Holdings Company Return On Equity Analysis

Reviva Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Reviva Pharmaceuticals Return On Equity

    
  -17.95  
Most of Reviva Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reviva Pharmaceuticals Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Reviva Pharmaceuticals Holdings has a Return On Equity of -17.9506. This is much lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.

Reviva Pharmaceuticals Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Reviva Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Reviva Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Reviva Pharmaceuticals competition to find correlations between indicators driving Reviva Pharmaceuticals's intrinsic value. More Info.
Reviva Pharmaceuticals Holdings is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Reviva Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

About Reviva Pharmaceuticals Financial Statements

Reviva Pharmaceuticals investors use historical fundamental indicators, such as Reviva Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Reviva Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Reviva Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, as well as for treating pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Reviva Pharmaceuticals is traded on NASDAQ Exchange in the United States.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Reviva Stock Analysis

When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.